Influence of zofenopril and low doses of hydrochlorothiazide on plasma lipoproteins in patients with mild to moderate essential hypertension.
The effects of zofenopril (ZOF) calcium, an anticonverting enzyme inhibitor, and of hydrochlorothiazide (HCT) on plasma lipids, lipoproteins and apoproteins were compared in 37 patients with sitting diastolic blood pressure (SDBP) of 95 to 110 mm Hg at the end of a placebo period of 4 weeks. In the randomized double-blind experiment, 16 males and 21 females were treated with either ZOF, 30 mg (n = 18) or HCT, 25 mg (n = 19), once daily. When a SDBP of less than 90 mm Hg was not reached after 4 weeks, the dose of the initial treatment was doubled. Lipoprotein determinations were repeated after 12 weeks of active treatment. Statistically significant decrease in blood pressure (P less than .001) was demonstrated in both treated groups. Total, low density (LDL) and high density (HDL) lipoprotein, cholesterol and triglyceride concentrations were not modified either by ZOF or HCT. Furthermore, LDL/HDL and HDL-2/HDL-3 ratios, apoproteins B, A and A-1 levels did not show any significant differences. Thus, ZOF and small doses of HCT do not cause deleterious effects in lipoprotein composition as reported in previous studies with higher dosage.